CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00033-07v1
14/8/978    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hauge, S.
Right arrow Articles by Haaheim, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hauge, S.
Right arrow Articles by Haaheim, L. R.
Clinical and Vaccine Immunology, August 2007, p. 978-983, Vol. 14, No. 8
1071-412X/07/$08.00+0     doi:10.1128/CVI.00033-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Quality and Kinetics of the Antibody Response in Mice after Three Different Low-Dose Influenza Virus Vaccination Strategies{triangledown}

Solveig Hauge,* Abdullah Madhun, Rebecca Jane Cox, and Lars Reinhardt Haaheim

Influenza Center, The Gade Institute, University of Bergen, Armauer Hansen Building, N-5021 Bergen, Norway

Received 15 January 2007/ Returned for modification 23 April 2007/ Accepted 20 June 2007

The threat of a new influenza pandemic has led to renewed interest in dose-sparing vaccination strategies such as intradermal immunization and the use of adjuvanted vaccines. In this study we compared the quality and kinetics of the serum antibody response elicited in mice after one or two immunizations with a split influenza A (H3N2) virus, using three different low-dose vaccination strategies. The mice were divided into four groups, receiving either a low-dose vaccine (3 µg hemagglutinin [HA]) intradermally or intramuscularly with or without aluminum adjuvant or the normal human vaccine dose (15 µg HA) intramuscularly. Sera were collected weekly after vaccination and tested in the hemagglutination inhibition, virus neutralization, and enzyme-linked immunosorbent assays. The antibody responses induced after intradermal or intramuscular low-dose vaccinations were similar and lower than those observed after the human vaccine dose. However, low-dose adjuvanted vaccine elicited a serum antibody response comparable to that elicited by the human dose, although the second immunization did not result in any increase in cross-reactive hemagglutination inhibition antibodies, and the peak serum antibody response was observed 1 week later than in the other vaccination groups. Our murine data suggest that the low-dose intradermal route does not show any obvious advantage over the low-dose intramuscular route in inducing a serum antibody response and that none of the low-dose vaccination strategies is as effective as intramuscular vaccination with the normal human dose. However, the low-dose aluminum-adjuvanted vaccine could present a feasible alternative in case of limited vaccine supply.


* Corresponding author. Mailing address: Influenza Center, The Gade Institute, University of Bergen, Armauer Hansen Building, N-5021 Bergen, Norway. Phone: 47 5597 4669. Fax: 47 5597 4689. E-mail: Solveig.Hauge{at}gades.uib.no

{triangledown} Published ahead of print on 27 June 2007.


Clinical and Vaccine Immunology, August 2007, p. 978-983, Vol. 14, No. 8
1071-412X/07/$08.00+0     doi:10.1128/CVI.00033-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.